Curr Pharm Des. 2019 May 12. Epub 2019 May 12. PMID: 31092175
The effects of quercetin supplementation on blood pressures and endothelial function among patients with metabolic syndrome and related disorders: A systematic review and meta-analysis of randomized controlled trials.
BACKGROUND: This systematic review and meta-analysis of randomized controlled trials (RCTs) was performed to determine the effect of quercetin administration on blood pressures and endothelial function among patients with metabolic syndrome (MetS) and related disorders.METHODS: We searched systematically online databases including Cochrane Library, EMBASE, MEDLINE, and Web of Science to identify the relevant RCTs until December 2018. Q-test and I2 statistics were applied to assess heterogeneity among included studies. Data were pooled using a random-effects model and weighted mean difference (WMD) was considered as the overall effect size.RESULTS: Out of 284 citations, 9 RCTs were included in the meta-analysis. We found a significant reduction in systolic plod pressure (SBP) (WMD: -1.54; 95% CI: -2.94, -0.13) and vascular cell adhesion molecule 1 (VCAM-1) (WMD: -23.52; 95% CI: -40.48, -6.56) following the intake of quercetin supplements. However, quercetin supplementation did not significantly affect diastolic blood pressure (DBP) (WMD: -2.15; 95% CI: -4.52, 0.21), E-selectin (WMD: 0.71; 95% CI: -0.97, 2.39), intercellular adhesion molecule 1 (ICAM-1) (WMD: 1.90; 95% CI: -6.67, 10.47) and endothelin-1 (WMD: -0.08; 95% CI: -0.16, 0.00).CONCLUSIONS: In summary, the current meta-analysis demonstrated that quercetin supplementation significantly reduced SBP and VCAM-1 levels, yet did not affect DBP, endothelin-1, E-selectin and ICAM-1 among patients with MetS and related disorders.